--- a
+++ b/clusters/9knumclustersv2/clust_1501.txt
@@ -0,0 +1,43 @@
+Stage Ta/b (>  cm) and grade  or  AND
+Clinical stages Ta-Ta N M (AJCC Criteria th Ed.). Staging must be done by treating investigator.
+Organ confined clinical TC or clinical Ta prostate cancer that is visualized on MR imaging
+Clinical stage TIC or Ta
+Clinical or pathologic stage T T disease including Ta and b if feasible to treat with radiation therapy
+Clinical stages Ta-Tb
+Curatively treated incidental prostate cancer (T/Ta)
+Prostate cancer clinical stage Ta and below
+Have, at entry, confirmed by a pathology report: Carcinoma in situ (CIS) only; Ta/T high-grade disease with concomitant CIS; or Ta/T high-grade disease without concomitant CIS
+Clinically localized disease (?Ta) and
+Incidental histologic finding of prostate cancer (Ta or Tb using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative
+Incidental histologic finding of prostate cancer (Ta or Tb using the tumor, nodes, metastasis [Tumor, node, metastases (TNM)] clinical staging system).
+Incidental histological finding of prostate cancer (TNM stage of Ta or Tb)
+Stage IIIC colorectal cancer (Ta, Na, M) or (T-a, Nb, M), or (Tb, N- N, M) (per AJCC th ed).
+Patients have either Cis or Cis with Ta and/or T disease at enrollment or in the past. For those patients with only Ta or T disease at enrollment AND with no history of Cis, they must have
+Clinical stages Tb  Ta
+Subjects with evidence of extraprostatic extension (Ta) or seminal vesicle involvement (Tb) on clinical evaluation
+Patients who are diagnosed with clinical stage Ta -Tc prostate cancer
+Incidental histologic finding of prostate cancer (TNM stage of Ta or Tb)
+Clinical stage T-/N-/M at presentation (patients with Ta/bN tumors will not be eligible)
+Clinical stage T-Ta N/X M disease
+Ta-d, N-N
+Incidental histologic finding of prostate cancer (TNM stage of Ta or Tb)
+Incidental histologic finding of prostate cancer (TNM stage of Ta or Tb)
+Ta and Ta squamous cell carcinoma of the glottic larynx (tumor limited to one vocal cord with normal cord mobility)
+Clinical stage T-Ta, N/x, M disease
+Known Abl-kinase TI or TA mutation
+Incidental histologic finding of prostate cancer (TNM stage of Ta or Tb).
+Have newly diagnosed or recurrent multi-focal Ta, large Ta, high grade Ta, carcinoma in situ (CIS) or T bladder cancer
+Incidental histological finding of prostate cancer (TNM stage of Ta or Tb)
+Patients must have a biopsy proven newly diagnosed locally confined, stage Ta, Ta or Tb prostate cancer
+Have histologically confirmed organ-confined prostate cancer - Clinical Stage T or Ta,
+Have non-metastatic prostate cancer and =< clinical Ta disease at diagnosis
+Have received a diagnosis of localized disease confined to the prostate, with no regional lymph node or distant metastasis (stages T, Ta, Tb, T, Ta, Tb)
+Received a diagnosis of localized disease confined to the prostate, with no regional lymph node or distant metastasis (stages T, Ta, Tb, T, Ta, Tb)
+Participants are eligible if they received a diagnosis of localized disease confined to the prostate, with no regional lymph node or distant metastasis (stages T, Ta, Tb, T, Ta, Tb)
+Received a diagnosis of localized disease confined to the prostate, with no regional lymph node or distant metastasis (stages T, Ta, Tb, T, Ta, Tb, Tc, T, Ta, Tb, Tc)
+Clinical stage =< Ta by digital rectal exam (DRE)
+Incidental histologic finding of prostate cancer (Ta or Tb using the tumor, nodes, metastasis [TNM] clinical staging system)
+Patient with intermediate risk, early-stage organ-confined prostate cancer (Ta up to Tb, N, M) and voluntarily chooses ExAblate thermal ablation as the non-invasive treatment, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy.
+Incidental histologic finding of prostate cancer (Ta or Tb using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative.
+Clinical stage: =< Ta & N or NX & M or MX
+Clinical stage T-Ta, N, M urothelial bladder cancer